Skip to main content
    N

    Nephros Inc (NEPH)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $3.00
    -0.05 (-1.64%)

    Market Cap: $33.15M

    Last updated: Nov 17, 2026 at 11:00 AM ET

    Nephros Inc (NEPH) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Nephros (NEPH) is expected to report earnings on Mar 10, 2027. In the quarter ended Sep 30, 2026, Nephros reported EPS of $0.05, above the $0.02 estimate. It beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    47%(14/30)
    Avg Surprise
    +36.87%
    Streak
    2 Q

    Upcoming Estimates

    Reports Mar 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.01
    Range$0.01 - $0.02
    5 analysts
    Revenue Consensus
    $5.47M
    Range$5.10M - $5.77M
    5 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.04
    Range$0.04 - $0.04
    1 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$0.00n/a
    30d ago$0.00n/a
    7d ago$0.03+33.3%
    Current$0.04
    Revenue Consensus
    $5.97M
    Range$5.88M - $6.06M
    2 analysts

    Next Report

    NEPH has an expected report date of Mar 10, 2027.

    NEPH Earnings Call

    The latest NEPH earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 30 quarters below that had an estimate, NEPH beat 14, missed 11 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $5.62M, up 18.1% from $4.76M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.05$0.02N/A+150.00%Beat+66.7%11 up, 1 downNov 5, 2026$5.62M
    Jun 30, 2026$0.06$0.01-$0.01 - $0.01+500.00%Beat+200.0%31 up, 1 downAug 6, 2026$6.02M
    Mar 31, 2026$0.01$0.01$0.01 - $0.010.00%In line-80.0%20 up, 1 downMay 7, 2026$5.21M
    Dec 31, 2025$0.01-$0.01N/A+200.00%Beat-66.7%20 up, 1 downMar 12, 2026$4.73M
    Sep 30, 2025$0.03-$0.02-$0.02 - -$0.02+250.00%Beat+50.0%20 up, 1 downNov 6, 2025$4.76M
    Jun 30, 2025$0.02-$0.02-$0.03 - -$0.02+200.00%BeatN/A20 up, 2 downAug 7, 2025$4.42M
    Mar 31, 2025$0.05-$0.01-$0.02 - $0.01N/AN/AN/A20 up, 1 downMay 15, 2025$4.88M
    Dec 31, 2024$0.03-$0.02-$0.02 - -$0.01+300.00%BeatN/A20 up, 0 downMar 24, 2025$3.87M
    Sep 30, 2024$0.02-$0.02-$0.02 - -$0.02+200.00%BeatN/A20 up, 0 downNov 7, 2024$3.52M
    Jun 30, 2024-$0.03-$0.01N/A-200.00%MissN/AN/A0 up, 0 downAug 8, 2024$3.25M
    Mar 31, 2024-$0.02-$0.04-$0.06 - -$0.02+50.00%BeatN/A20 up, 0 downMay 9, 2024$3.52M
    Dec 31, 2023-$0.06-$0.02-$0.04 - -$0.01-200.00%MissN/A20 up, 0 downMar 7, 2024$3.25M
    Sep 30, 2023-$0.02-$0.05-$0.08 - -$0.05+60.00%BeatN/A20 up, 0 downNov 8, 2023$3.74M
    Jun 30, 2023-$0.04-$0.05-$0.06 - -$0.05+20.00%BeatN/A20 up, 0 downAug 9, 2023$3.54M
    Mar 31, 2023-$0.03-$0.02-$0.02 - -$0.02-50.00%MissN/A10 up, 0 downMay 10, 2023$3.70M
    Dec 31, 2022-$0.10-$0.06-$0.07 - -$0.06-66.67%MissN/A20 up, 0 downMar 8, 2023$2.56M
    Sep 30, 2022-$0.31-$0.11-$0.12 - -$0.10-181.82%MissN/A30 up, 0 downNov 2, 2022$2.41M
    Jun 30, 2022-$0.12-$0.14-$0.16 - -$0.14+14.29%BeatN/A20 up, 0 downAug 10, 2022$2.85M
    Mar 31, 2022-$0.20-$0.11-$0.13 - -$0.08-81.82%MissN/A30 up, 0 downMay 4, 2022$2.16M
    Dec 31, 2021-$0.11-$0.11-$0.14 - -$0.100.00%In lineN/A3N/AFeb 23, 2022N/A
    Sep 30, 2021-$0.12-$0.11-$0.11 - -$0.10-9.09%MissN/A2N/ANov 4, 2021$2.58M
    Jun 30, 2021-$0.12-$0.11-$0.12 - -$0.10-9.09%MissN/A3N/AAug 5, 2021$2.27M
    Mar 31, 2021-$0.11-$0.11-$0.14 - -$0.090.00%In lineN/A3N/AMay 6, 2021$5.47M
    Dec 31, 2020-$0.08-$0.11-$0.12 - -$0.10+27.27%BeatN/A3N/AMar 1, 2021$2.33M
    Sep 30, 2020-$0.14-$0.14-$0.16 - -$0.110.00%In lineN/A3N/ANov 5, 2020$2.12M
    Jun 30, 2020-$0.19-$0.15-$0.17 - -$0.12-26.67%MissN/A3N/AAug 5, 2020$1.58M
    Mar 31, 2020-$0.13-$0.09N/A-44.44%MissN/A2N/AMay 6, 2020$2.53M
    Dec 31, 2019-$0.02-$0.11-$0.15 - -$0.08+81.82%BeatN/A3N/AFeb 27, 2020N/A
    Sep 30, 2019-$0.10-$0.10-$0.12 - -$0.070.00%In lineN/A3N/ANov 6, 2019N/A
    Jun 30, 2019-$0.14-$0.18N/A+22.22%BeatN/AN/AN/AAug 7, 2019$2.31M
    Mar 31, 2019-$0.18-$0.09N/A-100.00%MissN/AN/AN/AMay 8, 2019$1.77M
    Dec 31, 2018-$0.09N/AN/AN/AN/A-550.0%N/AN/AMar 12, 2019$1.61M
    Sep 30, 2018-$0.01N/AN/AN/AN/AN/AN/AN/ANov 8, 2018$1.72M
    Jun 30, 2018-$0.01N/AN/AN/AN/AN/AN/AN/AAug 8, 2018$1.37M
    Mar 31, 2018-$0.03N/AN/AN/AN/AN/AN/AN/AMay 9, 2018$985000
    Dec 31, 2017$0.02N/AN/AN/AN/AN/AN/AN/AFeb 26, 2018$1.30M
    Sep 30, 2017-$0.01N/AN/AN/AN/AN/AN/AN/ANov 9, 2017$916000
    Jun 30, 2017-$0.01N/AN/AN/AN/AN/AN/AN/AAug 8, 2017$859000
    Mar 31, 2017-$0.01N/AN/AN/AN/AN/AN/AN/AMay 9, 2017$734000
    Dec 31, 2016-$0.12N/AN/AN/AN/AN/AN/AN/AMar 20, 2017$746000
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.11. It was -$0.52 for the year ended Dec 31, 2016, the oldest of the 9 fiscal years below with reported EPS.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.11N/A
    Dec 31, 2024Not reportedN/A
    Dec 31, 2023-$0.15N/A
    Dec 31, 2022-$0.73N/A
    Dec 31, 2021-$0.46N/A
    Dec 31, 2020-$0.54N/A
    Dec 31, 2019-$0.44N/A
    Dec 31, 2018-$0.14N/A
    Dec 31, 2017-$0.01N/A
    Dec 31, 2016-$0.52N/A

    Earnings Calls

    The 7 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,800 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,8116
    2026Q2Jun 30, 20264,6267
    2026Q1Mar 31, 20264,6037
    2025Q4Dec 31, 20253,4116
    2025Q3Sep 30, 20254,8947
    2024Q3Sep 30, 20243,5157
    2024Q2Jun 30, 20242,4085

    2026Q3 Earnings Call

    Opening remarks

    Kirin Smith Conference Call Moderator Thank you, everyone, and good afternoon. This is Kirin Smith with PCG Advisory. Thank you all for participating in Nephros' third quarter 2026 conference call. Before we begin, I would like to caution that comments made during this conference call by management will contain forward-looking statements regarding the operations and future results of Nephros. I encourage you to review Nephros' filings with the Securities and Exchange Commission, including, without limitation, the company's Forms 10-K and 10-Q, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Factors that may affect the company's results include, but are not limited to, Nephros' ability to successfully, timely, and cost-effectively market and sell its products and service offerings; the rate of adoption of its products and services by hospitals and other healthcare providers; the success of its commercialization efforts; and the effect of existing and new regulatory requirements on Nephros' business, as well as other economic and competitive factors. The content of this conference call contains time-sensitive information that is accurate only as of the date of the live call, today, November 6, 2026. The company undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call, except as required by law. I would now like to turn the call over to Nephros' President and Chief Executive Officer, Robert Banks. Robert, please go ahead.

    Robert Banks President and Chief Executive Officer Thank you, Kirin, and good afternoon, everyone. The third quarter of 2026 was another strong quarter for Nephros, and more importantly, provides additional evidence of the durability of the growth we have been building over the last several years. We generated approximately $5.6 million in revenue, an increase of 18% over the third quarter of 2025. This followed the record $6 million we reported in the second quarter. I think that sequence is important. A record quarter is exciting. Following a record quarter with another quarter of strong double-digit year-over-year growth tells us much more about the underlying business. For the first nine months of 2026, revenue reached approximately $16.9 million, an increase of 20% over the same period last year. Core programmatic revenue increased 19% over that nine-month period. Importantly, this is profitable revenue growth, where net income and adjusted EBITDA increased to approximately $500,000 and approximately $600,000, respectively. Our trailing 12-month revenue has now surpassed $21 million. When you look at those results together, I believe they demonstrate that Nephros is becoming a larger, stronger, and increasingly durable business. Our core programmatic business remains the foundation of that growth. Programmatic product revenue increased approximately 8% during the third quarter compared with last year.

    Frequently Asked Questions About NEPH

    When is Nephros's next earnings date?

    Nephros's next earnings report is expected for Mar 10, 2027.

    Did NEPH beat earnings estimates last quarter?

    Yes. Nephros reported EPS of $0.05 for the quarter ended Sep 30, 2026, above the $0.02 estimate, a 150.00% surprise.

    What EPS do analysts expect from NEPH next quarter?

    The consensus EPS estimate for Nephros for the quarter ending Dec 31, 2026 is $0.01 from 5 analysts, with estimates from $0.01 to $0.02.

    How often does NEPH beat earnings estimates?

    Nephros beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate, with an average surprise of +225.00%.